Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia.
Keywords: 
LBH589
Acute Lymphoblastic Leukemia
Epigenetics
Histone
Mouse model
Issue Date: 
2012
Publisher: 
Nature Publishing Group
ISSN: 
0887-6924
Citation: 
Vilas-Zornoza A, Agirre X, Abizanda G, Moreno C, Segura V, De Martino Rodriguez A, et al. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia. Leukemia 2012 Jul;26(7):1517-1526.
Abstract
Histone deacetylases (HDACs) have been identified as therapeutic targets due to their regulatory function in chromatin structure and organization. Here, we analyzed the therapeutic effect of LBH589, a class I-II HDAC inhibitor, in acute lymphoblastic leukemia (ALL). In vitro, LBH589 induced dose-dependent antiproliferative and apoptotic effects, which were associated with increased H3 and H4 histone acetylation. Intravenous administration of LBH589 in immunodeficient BALB/c-RAG2(-/-)γc(-/-) mice in which human-derived T and B-ALL cell lines were injected induced a significant reduction in tumor growth. Using primary ALL cells, a xenograft model of human leukemia in BALB/c-RAG2(-/-)γc(-/-) mice was established, allowing continuous passages of transplanted cells to several mouse generations. Treatment of mice engrafted with T or B-ALL cells with LBH589 induced an in vivo increase in the acetylation of H3 and H4, which was accompanied with prolonged survival of LBH589-treated mice in comparison with those receiving vincristine and dexamethasone. Notably, the therapeutic efficacy of LBH589 was significantly enhanced in combination with vincristine and dexamethasone. Our results show the therapeutic activity of LBH589 in combination with standard chemotherapy in pre-clinical models of ALL and suggest that this combination may be of clinical value in the treatment of patients with ALL.

Files in This Item:
Thumbnail
File
Vilas-Zornoza LBH and ALL Manuscript Revised.pdf
Description
Size
150.55 kB
Format
Adobe PDF
Thumbnail
File
Vilas-Zornoza LBH and ALL Table1 Revised.pdf
Description
Size
16.13 kB
Format
Adobe PDF
Thumbnail
File
Figure1.pdf
Description
Size
74.56 kB
Format
Adobe PDF
Thumbnail
File
Figure2.pdf
Description
Size
110.85 kB
Format
Adobe PDF
Thumbnail
File
Figure3.pdf
Description
Size
86.95 kB
Format
Adobe PDF
Thumbnail
File
Figure4.pdf
Description
Size
97.07 kB
Format
Adobe PDF
Thumbnail
File
Figure5.pdf
Description
Size
187.15 kB
Format
Adobe PDF
Thumbnail
File
FigureS1.pdf
Description
Size
82.22 kB
Format
Adobe PDF
Thumbnail
File
FigureS2.pdf
Description
Size
113.45 kB
Format
Adobe PDF
Thumbnail
File
FigureS3.pdf
Description
Size
146.06 kB
Format
Adobe PDF
Thumbnail
File
FigureS4.pdf
Description
Size
123.06 kB
Format
Adobe PDF
Thumbnail
File
FigureS5.pdf
Description
Size
523.95 kB
Format
Adobe PDF
Thumbnail
File
FigureS6.pdf
Description
Size
411.86 kB
Format
Adobe PDF
Thumbnail
File
FigureS7.pdf
Description
Size
15.79 kB
Format
Adobe PDF
Thumbnail
File
FigureS8.pdf
Description
Size
15.26 kB
Format
Adobe PDF
Thumbnail
File
FigureS9.pdf
Description
Size
30.88 kB
Format
Adobe PDF
Thumbnail
File
Vilas-Zornoza Legends to Supplementary Figure Revised.pdf
Description
Size
111.29 kB
Format
Adobe PDF
Thumbnail
File
Vilas-Zornoza LBH and ALL Supplementary Materials and Methods Revised.pdf
Description
Size
65.06 kB
Format
Adobe PDF


Statistics and impact
0 citas en
0 citas en

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.